What one share of Karyopharm Therapeutics holds
We are a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development and commercialization of first-in-class drugs directed against nuclear export for the treatment of cancer.
Karyopharm Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $7.58 |
|---|---|
| Profit | −$11.62 |
| Cash and investments | $2.42 |
| Book value | −$14.56 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2011 | $2.30 | −$154.00 | $5.62 | −$133.30 | — | −$189.00 |
| 2012 | $5.40 | −$134.20 | $1.02 | −$132.10 | — | — |
| 2013 | $1.00 | −$83.90 | $0.14 | −$75.00 | — | — |
| 2014 | $0.11 | −$36.51 | $1.37 | −$26.15 | — | $94.86 |
| 2015 | $0.11 | −$49.77 | $0.60 | −$40.19 | — | $82.96 |
| 2016 | $0.06 | −$43.80 | $0.03 | −$33.76 | — | $58.10 |
| 2017 | $0.52 | −$42.15 | $0.02 | −$24.11 | — | $39.21 |
| 2018 | $8.01 | −$47.13 | $0.62 | −$42.66 | — | $45.17 |
| 2019 | $9.90 | −$48.32 | $0.05 | −$46.25 | — | $11.42 |
| 2020 | $22.50 | −$40.87 | $0.03 | −$33.39 | — | $10.26 |
| 2021 | $41.84 | −$24.75 | $0.04 | −$21.40 | — | −$15.78 |
| 2022 | $28.78 | −$30.28 | $0.02 | −$27.42 | — | −$2.21 |
| 2023 | $19.17 | −$18.79 | $0.00 | −$12.17 | — | −$17.78 |
| 2024 | $17.18 | −$14.00 | $0.02 | −$15.10 | — | −$22.11 |
| 2025 | $13.36 | −$17.93 | $0.00 | −$6.89 | — | −$16.00 |
Common questions about Karyopharm Therapeutics
How much does one share of Karyopharm Therapeutics earn?
Over the last 12 months, Karyopharm Therapeutics lost $11.62 for each share on $7.58 of sales.
Does Karyopharm Therapeutics pay a dividend?
Karyopharm Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Karyopharm Therapeutics’s book value per share?
Karyopharm Therapeutics’s book value is negative (−$14.56 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of June 30, 2026.
How much cash and debt does each share of Karyopharm Therapeutics have?
Each share of Karyopharm Therapeutics has $2.42 of cash and investments, as of June 30, 2026.
Has Karyopharm Therapeutics bought back shares?
Karyopharm Therapeutics’s share count rose about 16235% from 2011 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.